ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 535

Examination of Diurnal and Daily Variation of the Multi-Biomarker Disease Activity (MBDA) Score in RA to Establish the Minimally Important Difference

David Chernoff1, Rebecca J. Bolce1, Ching Chang Hwang2, Xingbin Wang1, Alan Kivitz3 and Jeffrey R. Curtis4, 1Crescendo Bioscience Inc., South San Francisco, CA, 2Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, 3Altoona Center for Clinical Research, Duncansville, PA, 4Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disease Activity and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The biological variability in MBDA scores over a 24-hour period and day-to-day in patients with rheumatoid arthritis (RA) has not been well characterized. These data were obtained to determine a minimally important difference (MID) and establish a cut point for a meaningful change in MBDA scores over time.

Methods: 28 adults with clinically stable seropositive RA on stable medication (>8 weeks without changes), were recruited to a single US rheumatology research center. Serum samples were obtained 6 times over the first 24-hour period (8 AM, 12 PM, 4 PM, 8 PM, 12 AM and 8 AM) then at 12 PM in the next 24-hour period and at 8 AM the next two consecutive days, for a total of 9 time points. Diurnal variation was calculated using 6 time-points over the first 24 hours.  Daily variation was determined using 4 time points taken at 8 AM on successive days.  Combined diurnal and daily variation was calculated by using 9 time points over the four days. For each patient (n=28), changes in MBDA scores were calculated for all possible pairs of time points for: (a) Diurnal variation (15 possible pairs/patient, 420 total pairs), (b) Daily variation (6 possible pairs/patient, 168 total pairs) and (c) Diurnal and Daily variation (36 possible pairs/patient, 1008 total pairs).  The mean change in MBDA score was determined for all pairs in each of the 3 analyses. The MID was calculated as twice the standard deviation (SD) using all available data.

Results: 28 patients were recruited for the following MBDA disease activity categories: 6 in low, 13 in moderate and 9 in high.  Patient baseline characteristics were 64.3% women, mean age 61.9 years, mean MBDA score 39.3, and mean CDAI 19.9.  With 96.4% patients on DMARDs, 8 patients were receiving biologics (1 rituximab; 7 anti-TNF, 6 in combination with MTX). No patients were on glucocorticoids. During the first day, the greatest and lowest mean MBDA scores were observed at 12 AM (midnight) and 12 PM (noon), respectively (Figure). The mean absolute change (SD) of MBDA score for diurnal variation was 4.3 (4.2). The largest variability in MBDA scores was observed for patients in the low MBDA category. The mean absolute change was 4.3 (4.4) for daily variation and 4.5 (4.5) in the combined daily and diurnal variation analysis. The MID was calculated as 9. Approximately 91% of the absolute changes determined for all pairs of MBDA score were ≤9. 

Conclusion: Based upon short-term variability in the MBDA score among stable RA patients tested serially over time, the minimally important difference in the MBDA score was 9 units. Changes exceeding this threshold are unlikely to be due to diurnal and daily biological variation alone.  


Disclosure: D. Chernoff, Crescendo Bioscience Inc., 1,Crescendo Bioscience Inc., 3; R. J. Bolce, Crescendo Bioscience Inc., 3; C. C. Hwang, Crescendo Bioscience Inc., 1,Crescendo Bioscience Inc., 3; X. Wang, Crescendo Bioscience Inc., 3; A. Kivitz, None; J. R. Curtis, Roche/Genentech, UCB, Janssel, Corrona, Amgen, Pfizer, BMS, Crescendo, AbbVie, 2,Roche/Genentech, UCB, Janssel, Corrona, Amgen, Pfizer, BMS, Crescendo, AbbVie, 5.

To cite this abstract in AMA style:

Chernoff D, Bolce RJ, Hwang CC, Wang X, Kivitz A, Curtis JR. Examination of Diurnal and Daily Variation of the Multi-Biomarker Disease Activity (MBDA) Score in RA to Establish the Minimally Important Difference [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/examination-of-diurnal-and-daily-variation-of-the-multi-biomarker-disease-activity-mbda-score-in-ra-to-establish-the-minimally-important-difference/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/examination-of-diurnal-and-daily-variation-of-the-multi-biomarker-disease-activity-mbda-score-in-ra-to-establish-the-minimally-important-difference/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology